Overview

ALY688-SR in Generally Healthy Overweight or Obese Adults

Status:
Terminated
Trial end date:
2021-08-03
Target enrollment:
Participant gender:
Summary
First in human study of ALY688-SR administered as a subcutaneous injection
Phase:
Phase 1
Details
Lead Sponsor:
Allysta Pharmaceutical
Collaborator:
INC Research Australia Pty Ltd